Evidence of an effective new treatment for Alzheimer’s would create shock waves across healthcare given the extent of the global need among millions of patients.
But it could also be a major event in geopolitics, given what making progress in this highly complex disease would say about a country’s scientific capabilities.
So it is potentially significant that a Chinese company, Green Valley Pharmaceutical, has achieved the rare feat of getting a positive read-out in a Phase III trial in mild-to-moderate Alzheimer's disease.
"GV-971 could help diversify the portfolio of treatments for this terrible disease"
Full story here: